11º FORO MEDCAP R&D Medium Cap Leaders. Madrid, May 27, 2015

Transcription

1 11º FORO MEDCAP R&D Medium Cap Leaders Madrid, May 27, 2015

2 01. A NEW COMPANY

3 A NEW COMPANY Established: 2002 Spin-off from Natra Sector: Food supplements 2013 sales: 31.4 M 2013 EBITDA: 2.6 M Established: rd generation family owned company Sector: Pharma 2013 sales: M 2013 EBITDA: 13.6 M 3

4 BUSINESS AREAS Leveraging on R&D and specialised production capabilities 2014 sales: M Therapeutic areas Dermatology, gynecology, respiratory, antibiotics (specially, betalactam-), injectable generics and consumer healthcare Products Medicines (prescription and non-prescription), generic products based on special technologies, medical devices, food supplements and cosmetics R&D&i RJF Pharma (Own development s manufacture and sale) 78% M 41% Direct sales 37% Third-party distribution Innovation in new formulations and new clinical indications of existing molecules in the therapeutic areas above Innovation in injectable generics based on specialized production technology, in any therapeutic area RJF CDMO (Specialised contract development and manufacturing) 22% 34.3 M 13% Betalactam antibiotics and injectable generics 9% Basic formulations Services Manufacture of high-quality and high-standard specialized formulations: injectable, freezed dried vials of chemical molecules or biotech products, betalactam antibiotics in dedicated production plants and topical products Design, development, stabilization and lyophilization process for biological and/or chemical assets Fill and finish for batches of injectable innovative clinical trials Manufacture of traditional formulations Full regulatory support for product registration Development of innovative chemical or biological molecules in partnership with start-ups and research centres through open-innovation models. 4

5 BUSINESS STRUCTURE Diversified product portfolio and international presence DEVOLOPMENT AND PRODUCTION SITES Barcelona Spain Injectables, freeze dried products and oral formulations Toledo (2) Spain Oral and injectable pennicilins and cephalosporines Malmö Sweden Topical and dermatological formulations PRODUCTS / R+D / REGULATORY (*) Antibiotics and injectables Betalactam antibiotics Lyophilized injectable generics Specialities Dermatology Gynecology Respiratory Others Food supplements and consumer healthcare MARKETS Direct sales Spain France Nordic countries Benelux Portugal UK Over 100 marketing partners to reach 50 markets International distributors International licensees 5

6 02. R&D PIPELINE

7 RESEARCH PROJECTS PRESCRIPTION Area Patent Preclinical I II III Registry IV Launch Ginecology Y 2015 Pediatrics Y 2015 Dermatology Y 2018 Dermatology N 2018 Antibiotics N 2018 Dermatology N 2021 OTC Area Patent Preclinical I II III Registry IV Launch Ginecology Y 2020 Dermatology N 2016 Dermatology N 2015 Dermatology N 2017 Podology N 2017 Estimated launches in 2015 shall reach peak sales in 2019 totalling 18 M. 7

8 03. REIG JOFRE AND THE OPEN INNOVATION MODELS

9 CUANDO HABLAMOS DE INNOVACION no podemos pensar en el próximo año tenemos que pensar en lo que hay que hacer HOY para tener ÉXITO en 5 o 10 AÑOS.

10 El mercado es el mundo y la ESPECIALIZACIÓN la llave de entrada

11 1. Innovación de producto 2. Innovación en modelos de negocio en I+D+i

12 INNOVACION DE PRODUCTO EN REIG JOFRE GyencDX: kit de diagnóstico molecular de cáncer de endometrio NifePar: primer tratamiento oral para la amenaza de parto prematuro

13 INNOVACION EN MODELOS DE NEGOCIO EN I+D+i

14 Apuesta por nuevos modelos de interrelación entre empresas e instituciones

15 OPEN INNOVATION Reig Jofre expands its innovation potential by opening to new projects with external partners. We combine internal and external ideas and create different business models in order to collaborate with: - Start-ups - Pharmaceutical companies - Research groups - Public organizations, Universities and Hospitals for the development of innovative products. Innovating with partners by sharing risks and rewards 15

16 OPEN INNOVATION MODELS Innovating with partners by sharing the risks and the rewards Development Services Risk Sharing: invest In kind Vaccines US / Japan Projects Licenses Private-Public consortium Joint Venture Co-development

17 Av. de les Flors Sant Joan Despi Barcelona, Spain T Investor Relations